Indeed, one mechanism of the anti-obesity effect of glucagon-like peptide-1 (GLP-1) receptor agonists is satiety, i.e. reduced food intake and all its components such as salt. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.